MRD levels molecularly detected after induction therapy (day 78) are a good marker of treatment response and predictive of subsequent relapse of T-ALL patients.19 For this reason, we chose to analyse NRF2-AKR1C1-3 signaling activation in MRDneg vs. MRDpos (MRD >5 × 10−4) T-ALL patients at diagnosis as a reliable and representative distinction of therapy “sensitive” or “resistant” tumors, respectively. Here, NFE2L2 is linked to acute lymphoblastic leukemia.